Citations

Mayo Clinic

Showing 10 of 108572 citations.

Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast
Bodelón, Clara , Oh, Hannah , Chatterjee, Nilanjan , García‐Closas, Montserrat , Palakal, Maya, Sherman, Mark E. , Geller, Berta M., Vacek, Pamela M. , Weaver, Donald L. , Chicoine, Rachael E., Papathomas, Daphne, Xiang, Jackie , Patel, Deesha A. , Khodr, Zeina G. , Linville, Laura , Clare, Susan E. , Visscher, Daniel W., Mies, Carolyn, Hewitt, Stephen M. , Brinton, Louise A. , Storniolo, Anna Maria , He, Chunyan , Figueroa, Jonine D. , Pfeiffer, Ruth M. , Chanock, Stephen Jacob , Gierach, Gretchen L. , García-Closas, Montserrat , Figueroa, Jonine D

International Journal of Cancer | November 10, 2016 | Volume: 140 | Issue: 4 | Pages: 825-832

10.1002/ijc.30512 | PMID 27859137 Get It

Terminal duct lobular units (TDLUs) are the predominant source of future breast cancers, and lack of TDLU involution (higher TDLU counts, higher acini count per TDLU and the product of the two) is a breast cancer risk factor. Numerous breast cancer susceptibility single nucleotide polymorphisms (SNPs) have been identified, but whether they are associated with TDLU involution is unknown. In a pooled analysis of 872 women from two studies, we investigated 62 established breast cancer SNPs and relationships with TDLU involution. Poisson regression models with robust variance were used to calculate adjusted per‐allele relative risks (with the non‐breast cancer risk allele as the referent) and 95% confidence intervals between TDLU measures and each SNP. All statistical tests were two‐sided; P < 0.05 was considered statistically significant. Overall, 36 SNPs (58.1%) were related to higher TDLU counts although this was not statistically significant (p = 0.25). Six of the 62 SNPs (9.7%) were nominally associated with at least one TDLU measure: rs616488 (PEX14), rs11242675 (FOXQ1) and rs6001930 (MKL1) were associated with higher TDLU count (p = 0.047, 0.045 and 0.031, respectively); rs1353747 (PDE4D) and rs6472903 (8q21.11) were associated with higher acini count per TDLU (p = 0.007 and 0.027, respectively); and rs1353747 (PDE4D) and rs204247 (RANBP9) were associated with the product of TDLU and acini counts (p = 0.024 and 0.017, respectively). Our findings suggest breast cancer SNPs may not strongly influence TDLU involution. Agnostic genome‐wide association studies of TDLU involution may provide new insights on its biologic underpinnings and breast cancer susceptibility.
Anhidrosis in multiple system atrophy involves pre‐ and postganglionic sudomotor dysfunction
Fealey, Robert D., Sletten, David M., Mandrekar, Jay , Benarroch, Eduardo E. , Sandroni, Paola , Low, Phillip A. , Mandrekar, Jay N., Coon, Elizabeth A. , Singer, Wolfgang

Movement Disorders | November 10, 2016 | Volume: 32 | Issue: 3 | Pages: 397-404

10.1002/mds.26864 | PMID 27859565 Get It

AbstractBackgroundThe objective of this study was to characterize the degree, pattern, lesion site, and temporal evolution of sudomotor dysfunction in multiple system atrophy (MSA) and to evaluate differences by parkinsonian (MSA‐parkinsonism) and cerebellar (MSA‐cerebellar) subtypes.MethodsAll cases of MSA evaluated at Mayo Clinic Rochester between 2005 and 2010 with postganglionic sudomotor testing and thermoregulatory sweat test were reviewed. Pattern and lesion site (preganglionic, postganglionic, or mixed) were determined based on thermoregulatory sweat test and postganglionic sudomotor testing.ResultsThe majority of the 232 patients were MSA‐parkinsonism (145, 63%). Initial postganglionic sudomotor testing was abnormal in 59%, whereas thermoregulatory sweat test was abnormal in 95% of all patients. MSA‐parkinsonism patients were more likely to have an abnormal thermoregulatory sweat test compared with MSA‐cerebellar (98% versus 90%, P = 0.006) and had a higher mean percentage of anhidrosis (57%) compared with MSA‐cerebellar (48%; P = 0.033). Common anhidrosis patterns were regional (38%) and global (35%). The site of the lesion was preganglionic in 47% and mixed (preganglionic and postganglionic) in 41%. The increase in anhidrosis per year was 6.2% based on 70 repeat thermoregulatory sweat tests performed on 29 patients. The frequency of postganglionic sudomotor abnormalities increased over time.ConclusionsOur findings suggest: (1) sudomotor dysfunction is almost invariably present in MSA and even more common and severe in MSA‐parkinsonism than MSA‐cerebellar; (2) a preganglionic pattern of sweat loss is common in MSA; however, pre‐ and postganglionic abnormalities may coexist; and (3) the increasing frequency of postganglionic sudomotor dysfunction over time suggests involvement of postganglionic fibers or sweat glands later in the disease course. © 2016 International Parkinson and Movement Disorder Society
How can mate-pair sequencing be utilized for cancer patients?
Gao, Ge , Smith, David I, Smith, David I

Expert Review of Molecular Diagnostics | November 10, 2016 | Volume: 17 | Issue: 1 | Pages: 1-3

10.1080/14737159.2017.1259569 | PMID 27830954 Get It

The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts
Scherber, Robyn M. , Geyer, Holly L. , Dueck, Amylou C. , Cavazzina, Riccardo, Masciulli, Arianna, Scarano, Marco, Barbui, Tiziano , Scherber, Robyn Marie, Geyer, Holly Lynn, Dueck, A. C. , Kosiorek, Heidi , Finazzi, Guido , Vannucchi, Alessandro M. , Mesa, Ruben A.

Leukemia & Lymphoma | November 10, 2016 | Volume: 58 | Issue: 6 | Pages: 1481-1487

10.1080/10428194.2016.1246733 | PMID 27830999 Get It

Progressive Decline of Lung Function in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Zamora‐Legoff, Jorge A. , Krause, Megan L., Crowson, Cynthia S. , Ryu, Jay H. , Matteson, Eric L. , Ryu, Jay H

Arthritis & Rheumatology | November 10, 2016 | Volume: 69 | Issue: 3 | Pages: 542-549

10.1002/art.39971 | PMID 27788297 Get It

ObjectiveInterstitial lung disease (ILD) is associated with substantial morbidity in rheumatoid arthritis (RA), but very little is known about its long‐term progression. This study was undertaken to investigate the progression of pulmonary disease using a large single‐center cohort of patients with RA‐associated ILD.MethodsRecords of all patients with RA‐associated ILD seen at Mayo Clinic between 1998 and 2014, with at least 4 weeks follow‐up and at least 1 pulmonary function test, were identified and manually screened for study inclusion. Progression was defined as a diffusing capacity for carbon monoxide (DLco) <40% predicted (or patients whose illness was too advanced to undergo screening) or a forced vital capacity (FVC) <50% predicted. Time to progression was analyzed using the Kaplan‐Meier method.ResultsOf the 167 patients included in the study, 81 (49%) were female, with a mean ± SD age of 67 ± 10 years at diagnosis of ILD. Median follow‐up time from diagnosis of ILD was 3.3 years (range 0.01–14.8). One‐third of the patients required supplemental oxygen, 40% developed DLco <40% predicted, and 22% developed FVC <50% predicted within 5 years after ILD diagnosis. Usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP) was a risk factor for DLco progression (hazard ratio 3.29 [95% confidence interval 1.28–8.41]). Lower DLco and FVC at baseline increased the risk for progression to DLco <40% predicted and FVC <50% predicted, and higher rates of change in the first 6 months also increased the risk of progression.ConclusionProgressive loss of pulmonary function is common in RA‐associated ILD and is worse in patients with UIP than in those with NSIP. Predictors of progression in patients with RA‐associated ILD may aid clinicians in identifying patients at highest risk for progression of ILD.
Histone H4 Methyltransferase Suv420h2 Maintains Fidelity of Osteoblast Differentiation
Khani, Farzaneh , Thaler, Roman , Paradise, Christopher R. , Deyle, David R. , Julio, Marianne Kruijthof‐de, Galindo, Mario , Gordon, Jonathan A. R., Dudakovic, Amel , Wijnen, André J. van , van Wijnen, Andre J, Stein, Gary S. , van Wijnen, Andre J , van Wijnen, Andre J

Journal of Cellular Biochemistry | November 10, 2016 | Volume: 118 | Issue: 5 | Pages: 1262-1272

10.1002/jcb.25787 | PMID 27862226 Get It

ABSTRACTOsteogenic lineage commitment and progression is controlled by multiple signaling pathways (e.g., WNT, BMP, FGF) that converge on bone‐related transcription factors. Access of osteogenic transcription factors to chromatin is controlled by epigenetic regulators that generate post‐translational modifications of histones (“histone code”), as well as read, edit and/or erase these modifications. Our understanding of the biological role of epigenetic regulators in osteoblast differentiation remains limited. Therefore, we performed next‐generation RNA sequencing (RNA‐seq) and established which chromatin‐related proteins are robustly expressed in mouse bone tissues (e.g., fracture callus, calvarial bone). These studies also revealed that cells with increased osteogenic potential have higher levels of the H4K20 methyl transferase Suv420h2 compared to other methyl transferases (e.g., Suv39h1, Suv39h2, Suv420h1, Ezh1, Ezh2). We find that all six epigenetic regulators are transiently expressed at different stages of osteoblast differentiation in culture, with maximal mRNAs levels of Suv39h1 and Suv39h2 (at day 3) preceding maximal expression of Suv420h1 and Suv420h2 (at day 7) and developmental stages that reflect, respectively, early and later collagen matrix deposition. Loss of function analysis of Suv420h2 by siRNA depletion shows loss of H4K20 methylation and decreased expression of bone biomarkers (e.g., alkaline phosphatase/Alpl) and osteogenic transcription factors (e.g., Sp7/Osterix). Furthermore, Suv420h2 is required for matrix mineralization during osteoblast differentiation. We conclude that Suv420h2 controls the H4K20 methylome of osteoblasts and is critical for normal progression of osteoblastogenesis. J. Cell. Biochem. 118: 1262–1272, 2017. © 2016 Wiley Periodicals, Inc.
Who Should be Taking Care of Adolescent Testicular Torsion?
Husmann, Douglas A.

Journal of Urology | November 9, 2016 | Volume: 197 | Issue: 2 | Pages: 282-283

10.1016/j.juro.2016.11.024 | PMID 27838368 Get It

Educating Cardiovascular Fellows in the Contemporary Era
Nishimura, Rick A., Warnes, Carole A.

JAMA Cardiology | November 9, 2016 | Volume: 2 | Issue: 2 | Pages: 119

10.1001/jamacardio.2016.4084 | PMID 27829083 Get It

Keep Swimming Toward Precision Medicine Discoveries
Schimmenti, Lisa A. , Schimmenti, Lisa A

Zebrafish | November 9, 2016 | Volume: 13 | Issue: 6 | Pages: 545-547

10.1089/zeb.2016.1384 | PMID 27828765 Get It

Approach to Management of Coccidioidomycosis in Patients Receiving Inhibitors of Tumor Necrosis Factor-α
Blair, Janis E. , Wack, Elizabeth E., Mertz, Lester E., Galgiani, John N.

Infectious Diseases in Clinical Practice | November 9, 2016 | Volume: 25 | Issue: 4 | Pages: 184-192

10.1097/ipc.0000000000000466 Get It

Abstract Inhibitors of tumor necrosis factor-α (TNFIs) have revolutionized the treatment for patients with a variety of inflammatory illnesses, including rheumatoid arthritis, psoriasis and psoriatic arthritis, ankylosing spondylitis, and other inflammatory diseases, and have improved the outcomes and quality of life for such patients. Endemic fungal infections, such as coccidioidomycosis, are observed to occur in persons who are treated with these agents and who live in the Coccidioides-endemic area with similar frequency as persons in the general, healthy public but with an increased likelihood of symptomatic infection and extrapulmonary dissemination. Because the control of coccidioidal infections requires the formation and maintenance of granuloma, it is not unexpected that TNFIs, which inhibit granuloma formation, seem to increase the risk of clinical disease. No guidelines exist to address the prevention and management of disease in patients whose treatment course with TNFIs is complicated by subclinical or clinical coccidioidal infection. Therefore, we reviewed the available medical literature and offer suggestions to the approach and treatment of patients with various forms of coccidioidomycosis before and during therapy with TNFIs.